| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy D Finzi, J Blankson, JD Siliciano, JB Margolick, K Chadwick, T Pierson, ... Nature medicine 5 (5), 512-517, 1999 | 2681 | 1999 |
| Control of HIV despite the discontinuation of antiretroviral therapy J Lisziewicz, E Rosenberg, J Lieberman, H Jessen, L Lopalco, R Siliciano, ... New England Journal of Medicine 340 (21), 1683-1683, 1999 | 426 | 1999 |
| Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication F Lori, A Malykh, A Cara, D Sun, JN Weinstein, J Lisziewicz, RC Gallo Science 266 (5186), 801-805, 1994 | 394 | 1994 |
| Control of SIV rebound through structured treatment interruptions during early infection F Lori, MG Lewis, J Xu, G Varga, DE Zinn Jr, C Crabbs, W Wagner, ... Science 290 (5496), 1591-1593, 2000 | 231 | 2000 |
| Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. J Lisziewicz, D Sun, J Smythe, P Lusso, F Lori, A Louie, P Markham, ... Proceedings of the National Academy of Sciences 90 (17), 8000-8004, 1993 | 173 | 1993 |
| Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. J Lisziewicz, D Sun, M Klotman, S Agrawal, P Zamecnik, R Gallo Proceedings of the National Academy of Sciences 89 (23), 11209-11213, 1992 | 154 | 1992 |
| Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. J Lisziewicz, D Sun, V Metelev, P Zamecnik, RC Gallo, S Agrawal Proceedings of the National Academy of Sciences 90 (9), 3860-3864, 1993 | 151 | 1993 |
| Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. J Lisziewicz, D Sun, FF Weichold, AR Thierry, P Lusso, J Tang, RC Gallo, ... Proceedings of the National Academy of Sciences 91 (17), 7942-7946, 1994 | 146 | 1994 |
| Structured treatment interruptions for the management of HIV infection F Lori, J Lisziewicz Jama 286 (23), 2981-2987, 2001 | 136 | 2001 |
| DermaVir: a novel topical vaccine for HIV/AIDS J Lisziewicz, J Trocio, L Whitman, G Varga, J Xu, N Bakare, P Erbacher, ... Journal of investigative dermatology 124 (1), 160-169, 2005 | 131 | 2005 |
| Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance F LORI, AG MALYKH, A FOLI, R MASERATI, A DE ANTONI, L MINOLI, ... AIDS research and human retroviruses 13 (16), 1403-1409, 1997 | 103 | 1997 |
| Mutations in the pol Gene of Human Immunodeficiency Virus Type 1 in Infected Patients Receiving Didanosine and Hydroxyurea Combination Therapy AD Antoni, A Foli, J Lisziewicz, F Lori Journal of Infectious Diseases 176 (4), 899-903, 1997 | 103 | 1997 |
| Structured treatment interruptions to control HIV-1 infection F Lori, R Maserati, A Foli, E Seminari, J Timpone, J Lisziewicz The Lancet 355 (9200), 287-288, 2000 | 101 | 2000 |
| Control of viral rebound through therapeutic immunization with DermaVir J Lisziewicz, J Trocio, J Xu, L Whitman, A Ryder, N Bakare, MG Lewis, ... Aids 19 (1), 35-43, 2005 | 96 | 2005 |
| Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters … F Lori, H Jessen, J Lieberman, D Finzi, E Rosenberg, C Tinelli, B Walker, ... Journal of Infectious Diseases 180 (6), 1827-1832, 1999 | 94 | 1999 |
| Direct analysis of mitochondrial toxicity of antiretroviral drugs A Foli, F Benvenuto, G Piccinini, A Bareggi, A Cossarizza, J Lisziewicz, ... Aids 15 (13), 1687-1694, 2001 | 90 | 2001 |
| Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression. J Lisziewicz, J Rappaport, R Dhar The New biologist 3 (1), 82-89, 1991 | 87 | 1991 |
| Single DermaVir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals J Lisziewicz, N Bakare, SA Calarota, D Bánhegyi, J Szlávik, E Ujhelyi, ... PloS one 7 (5), e35416, 2012 | 86 | 2012 |
| Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns J Lisziewicz, A Foli, M Wainberg, F Lori Drug safety 26, 605-624, 2003 | 76 | 2003 |
| Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells J Lisziewicz, DI Gabrilovich, G Varga, J Xu, PD Greenberg, SK Arya, ... Journal of Virology 75 (16), 7621-7628, 2001 | 74 | 2001 |
